IP Library Granted Patent US 11,020,399
Granted Patent B2
US 11,020,399 · App. 16/359,419 · Granted Jun 1, 2021

Intermediates useful in the synthesis of compounds as modulators of protein kinases

Inventors: Dhanapalan Nagarathnam (Bethany, CT); Swaroop K. Vakkalanka (La Chaux-de-Fonds, CH); Meyyappan Muthuppalaniappan (Hyderabad, IN); Srikant Viswanadha (Hyderabad, IN); Govindarajulu Babu (Hyderabad, IN); Prashant K. Bhavar (Hyderabad, IN)
Assignee: RHIZEN PHARMACEUTICALS SA
A61K31/519A61K31/185A61K31/52A61K31/5355A61K31/5377A61K45/06C07D311/22C07D311/36C07D405/06C07D473/18C07D473/34C07D473/40C07D487/04Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,399
App. No.
16/359,419
Granted
Jun 1, 2021
Kind
B2
Abstract

The present invention provides compounds of formula (10), formula (12), formula (14) and formula (15) wherein R, R 1 , R 2 , Cy 1 and X are as described herein.

Claims (11)

1. A compound of formula (10), formula (12), formula (14), or formula (15):

wherein:

Cy 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

X is halogen;

R is halogen, —CN, —NO 2 , —C(O)R x , —C(O)NR x R y , —C(O)ONR x R y , —C(O)OR x , —C(S)R x , —NR x R y , —NR x C(O)R y , —NR x C(O)NR x R y , —NR x C(O)OR y , —NR x C(S)R y , —NR x C(S)NR x R y , —NR x S(O)R x , —NR x S(O) 2 R y , —S(O)NR x R y , —S(O) 2 NR x R y , —ONO 2 , —OR x , —OR x C(O)NR x R y , —OR x C(O)OR x , —OC(O)NR x R y , —OC(O)R x , —SR x , —S(O)R x , —S(O) 2 R x , —R x C(O)NR x R y , —R x C(O)OR y , —R x C(O)R y , —R x NR y C(O)R z , —R x OC(O)R y , —R x OR y , substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1 is hydrogen, halogen, or substituted or unsubstituted C 1-6 alkyl;

R 2 is hydrogen, halogen, or substituted or unsubstituted C 1-6 alkyl; and

each occurrence of R x , R y , and R z is independently hydrogen; or

each occurrence of R x , R y , and R z is independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

wherein the term “substituted” refers to substitution by one or more substituents independently selected from the group consisting of halogen, cyano, alkyl, alkylheterocyclyl, alkylaryl, —C(O)NH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)O(alkyl), —NH 2 , —NH(alkyl), —N(alkyl) 2 , —NHC(O)(alkyl), hydroxy, alkoxy, fluorinated alkoxy, —O-heterocyclyl, —S(alkyl), —S(O) 2 NH 2 , —S(O) 2 NH(alkyl), —S(O) 2 N(alkyl) 2 , —S(O) 2 NH(cycloalkyl), —S(O) 2 N(cycloalkyl) 2 , heterocyclyl, and heteroaryl.

2. The compound of claim 1 , wherein the compound is selected from the group consisting of:

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 6, 2021
From: RHIZEN PHARMACEUTICALS AG
To: RHIZEN PHARMACEUTICALS AG
Reel/Frame 057836/0286 →
CHANGE OF ADDRESS Recorded Mar 22, 2021
From: RHIZEN PHARMACEUTICALS SA
To: RHIZEN PHARMACEUTICALS SA
Reel/Frame 056775/0375 →
Priority Claims (2)
IN 1542/CHE/2011 · May 4, 2011 · national
IN 81/CHE/2012 · Jan 9, 2012 · national
Continuity (3)
Division 15677614 · Aug 15, 2017
Continuation 13464587 · May 4, 2012
Related Publication 20190282581A1 · Sep 19, 2019